Category: Include on Menu
-
Kroger issues cautious outlook as new CEO takes charge
Kroger (NYSE:KR) released its forecast for the current fiscal year, with guidance for both sales and profits coming in below Wall Street expectations as newly appointed CEO Greg Foran begins his tenure at a time of uncertainty around consumer spending. U.S. households continue to face several economic pressures, including elevated living costs, a labor market…
-
Distribution Solutions misses Q4 estimates as profits fall, shares drop
Distribution Solutions Group (NASDAQ:DSGR) reported fourth-quarter results that fell short of Wall Street expectations, with weaker profitability despite stable revenue. Sales for the quarter totaled $481.6 million, essentially flat from a year earlier and below analysts’ estimates of $496.3 million. Adjusted earnings per share came in at $0.18, significantly under the consensus forecast of $0.32.…
-
Helus Pharma reports encouraging Phase 2 results for HLP004 anxiety treatment
Helus Pharma (NASDAQ:HELP) reported positive topline Phase 2 signal-detection results for its investigational therapy HLP004 in adults with moderate-to-severe generalized anxiety disorder (GAD) who remained symptomatic despite standard antidepressant treatment. The study enrolled 36 patients who received two intramuscular doses of HLP004 or placebo, administered three weeks apart while continuing their existing standard-of-care therapy. Patients…
-
Medicus Pharma reports positive Phase 2 results for SkinJect skin cancer therapy
Medicus Pharma (NASDAQ:MDCX) said its SkinJect microneedle therapy showed encouraging results in a Phase 2 study evaluating the treatment for nodular basal cell carcinoma. The SKNJCT-003 trial tested the company’s Doxorubicin Microneedle Array, a non-invasive therapy designed to treat skin cancer. In the 200-microgram dose cohort at Day 57, the treatment achieved 73% clinical clearance…
-
Palladyne AI highlights transformational 2025 as acquisitions boost backlog
Palladyne AI Corp (NASDAQ:PDYN) reported fourth-quarter and full-year 2025 results, pointing to a year of strategic transformation driven by acquisitions and expansion into defense and aerospace technologies. The company said its purchases of GuideTech, Warnke Precision Machining and MKR Fabricators in November 2025, alongside the launch of Palladyne Defense, marked a shift from a pure…
-
Fusion Fuel unit Al Shola Gas secures $1.16 million LPG engineering contracts in Dubai
Fusion Fuel Green (NASDAQ:HTOO) said its indirectly held subsidiary Al Shola Al Modea Gas Distribution has been awarded two engineering subcontracts in Dubai valued at about $1.16 million. The contracts cover the design, supply, installation, testing and commissioning of centralized LPG systems across multiple buildings within two residential developments in the United Arab Emirates. Work…
-
Blue Hat to carry out 1-for-50 reverse stock split starting March 6
Blue Hat Interactive Entertainment Technology (NASDAQ:BHAT) said it plans to implement a 1-for-50 reverse stock split of its ordinary shares, effective Friday, March 6, 2026. Trading on a split-adjusted basis is set to begin at the market open on March 6. As of March 2, the company had 113,012,000 ordinary shares outstanding with a par…
-
FTC Solar shares tumble on weak first-quarter revenue outlook
FTC Solar (NASDAQ:FTCI) shares dropped sharply in premarket trading Thursday after the company issued a first-quarter revenue forecast that came in well below market expectations. The solar tracker manufacturer said it expects Q1 revenue of $20 million to $25 million, far short of analysts’ projections of about $35.1 million, according to LSEG data. FTC Solar…
-
Olaplex posts modest Q4 sales growth, swings to annual loss
Olaplex Holdings (NASDAQ:OLPX) reported slightly higher fourth-quarter sales but posted a wider loss as the haircare group navigated mixed channel performance and continued its strategic transformation. Net sales for the fourth quarter rose 4.3% year over year to $105.1 million. The company recorded a net loss of $13.1 million, compared with a loss of $8.8…
-
BioXcel posts encouraging Phase 2 results for opioid withdrawal therapy BXCL501
BioXcel Therapeutics (NASDAQ:BTAI) reported positive topline results from a Phase 2 investigator-sponsored trial evaluating its experimental therapy BXCL501 for the treatment of opioid withdrawal symptoms in adults undergoing methadone tapering. The study, funded by the National Institute on Drug Abuse, enrolled 80 participants diagnosed with opioid use disorder. Researchers compared BXCL501 administered at doses of…